All In Biotech

Drug Trial Radar · NCT02813070

Comparison of PET Amyloid Imaging in Japanese and Western Subjects

An Open-label Study to Assess Brain Uptake and Safety of Flutemetamol F 18 Injection in Japanese Subjects With Probable Alzheimer's Disease, Subjects With Amnestic Mild Cognitive Impairment and Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jun 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Oct 2012

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Jun 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a Phase 2, multicenter study to assess the extent and patterns of \[18F\] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable Alzheimer's disease (pAD), and to assess the reproducibility of brain uptake and of image interpretation. Subjects underwent open-label intravenous (i.v.) administration of Flutemetamol F 18 Injection and Positron emission tomography (PET) imaging of the brain. Blinded visual image reads were performed by 10 independent board-certified readers (5 Japanese and 5 non-Japanese) with nuclear medicine image interpretation experience. The blinded visual assessments were compared with the subject's clinical diagnoses, and the agreement between the image interpretations made by the 2 groups of readers (Japanese and non-Japanese) was determined.

Conditions

  • Mild Cognitive Impairment
  • Alzheimer's Disease
  • Healthy

Interventions

  • [18F] FlutemetamolDrug

    PET brain imaging and Magnetic resonance brain imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese ReadersTime frame: Up to 90 minutes after investigational medicinal product (IMP) administration
  2. Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese ReadersTime frame: Up to 90 minutes after IMP administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.